NCT01639625

Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application

Open Clinical Trial, Uncontrolled in Patients Bearing Squamous Cell Carcinoma or Adenocarcinoma of the Cervix Stage IIA and IIB FIGO Classification Treated With Radiotherapy External Endocavitary Brachytherapy + Concurrent Hemotherapy Weekly Systemic and Local Application of CIGB-300 Dose Escalation

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Laboratorio Elea Phoenix S.A. · Industry
• Sex: Female
• Age: 21 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

They include patients who are candidates to complete concurrent treatment with endocavitary brachytherapy External radiation therapy + more QT based weekly cisplatin.

Conditions

• Squamous Cell Carcinoma of the Cervix
• Adenocarcinoma of the Cervix

Interventions

Type	Name	Description
DRUG	CIGB300	CIGB300: 15 mg, 35 mg and 70 mg All groups will receive CIGB-300 for local application.

Timeline

• Start date: 2011-05-01
• Primary completion: 2015-09-01
• Completion: 2016-01-01
• First posted: 2012-07-13
• Last updated: 2016-08-02

Locations

1 site across 1 country: Argentina